Marker Therapeutics ((MRKR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Marker Therapeutics is conducting a Phase 1 study titled A Phase 1 Study of Allogenic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products (MT-401-OTS) Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID). The study aims to evaluate the safety and efficacy of MT-401-OTS in patients with relapsed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS), focusing on those with intermediate to very-high-risk profiles. This research is significant as it explores a novel treatment avenue for these challenging conditions.
Intervention/Treatment: The intervention being tested is MT-401-OTS, an off-the-shelf cellular therapy product administered via IV infusion. It is designed to target multiple tumor-associated antigens, potentially offering a new therapeutic option for patients with relapsed AML or MDS.
Study Design: This interventional study follows a non-randomized, sequential model with no masking. It involves dose escalation to determine the optimal safe dosage of MT-401-OTS, with the primary purpose of treatment.
Study Timeline: The study began on August 7, 2024, with the latest update submitted on August 26, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment status, which is currently active.
Market Implications: The progress of this study could influence Marker Therapeutics’ stock performance positively by showcasing potential advancements in AML and MDS treatment. Investor sentiment may be buoyed by the innovative approach and collaboration with reputable institutions like the University of Kansas Medical Center and City of Hope. Competitors in the oncology space will be closely watching these developments as they could shift market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.